Table 3 First recurrence (r1) after endoscopic nasopharyngectomy
From: 5-year outcomes of salvage endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma
Patient # | Location of first recurrence | r1TNM / r1Stage | Time to second recurrence (months) | Subsequent treatment | Surgical margins | Adjunctive therapy |
|---|---|---|---|---|---|---|
P1 | Nasopharynx, posterior inferior turbinate | T1N0M0 / Stage 1 | 24.6 | Endoscopic nasopharyngectomy, partial medial maxillectomy | – | none |
P2 | Fossa of Rossenmuller | T1N0M0 / Stage 1 | 5.6 | Endoscopic nasopharyngectomy | – | none |
P4 | Parapharyngeal space (carotid extension) | T2N0M0 / Stage 2 | 34.5 | Chemo via docetaxel and cisplatin (currently alive with stable disease) | N/A | N/A |
P8 | Nasopharynx; pterygomaxillary fossa; infratemporal fossa | T4N0M0 / Stage 4 | 25.2 | Endoscopic nasopharyngectomy, dissection of pterygomaxillary fossa, dissection of infratemporal fossa | + (infratemporal fossa) | CyberKnife SRT (1.6Gy) |
P10 | Parapharyngeal space (carotid extension), skullbase, bilateral retropharyngeal nodes | T3N2M0 / Stage 3 | 14.4 | Chemo via docetaxel and cetuximab (currently alive in comfort care) | N/A | N/A |
P11 | Sphenoid sinus; pterygopalatine fossa | T3N0M0 / Stage 3 | 9 | Sphenoidotomy; pterygopalatine fossa dissection | – | None |